Viral Vector & Plasmid DNA Manufacturing - Global Market Outlook (2018-2027)

Global Viral Vector & Plasmid DNA Manufacturing market is accounted for $321.60 million in 2018 and is expected to reach $1,178.24 million by 2027 growing at a CAGR of 15.1% during the forecast period. Some of the factors such as raise in alertness regarding gene therapy and raise in funding for R&D performance pertaining to gene therapy are driving the growth of the market. However, high price linked with gene therapies is likely to hamper the market growth.

Viral Vector & Plasmid DNA are commodities of gene therapy, which are used for the dealing of a great number of diseases. The advantages of gene vaccines and therapy in excess of conventional vaccines and therapies include the capacity to bring a wide variety of immune response types.  A number of clinical studies are being conducted on this market, which highlight the potential of gene therapy to deal with significant medical needs, and have initiated a surge of savings in drug expansion and commercialization of these therapies.

By vector type, plasmid DNA segment is likely to have a huge demand in the forecast period due to the clinical research applications in gene therapy and genetic vaccination. The command and therapeutic applications for plasmid DNA (pDNA) have fast grown and extended.

On the basis of geography, North America is estimated to have a huge demand owing to the growing investments in gene therapy commodities in the United States in recent years. In the United States, rigid support and patient encouragement have pressed rare illness clinical research to the centre stage.

Some of the key players in Viral Vector & Plasmid DNA Manufacturing Market include Lonza, Catapult, uniQure N.V., FUJIFILM Diosynth Biotechnologies, Kaneka Eurogentec S.A., Oxford Biomedica, Spark Therapeutics, Inc., Cobrabiologics, Merck KGaA, Brammer Bio, Cell and Gene Therapy Catapult, FinVector Vision Therapies, MassBiologics, SIRION Biotech and Thermo Fisher Scientific.

Vector Types Covered:
• Viral Vectors
• Non-Viral Vectors

Workflows Covered:
• Downstream Processing
• Upstream Processing

Diseases Covered:
• Infectious Diseases
• Cancer
• Genetic Disorders

Sales Channels Covered:
• Direct Sales
• Channel Sales

Applications Covered:
• Vaccinology
• Antisense & RNAi, & Molecular Therapy
• Cell Therapy
• Cancer
• Viral Infections
• Gene Therapy
• Inherited Disorders
• Viral Vaccines
• Protein Expression Studies
• Formulation Development

End Users Covered:
• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes
• Immunotherapy
• DNA Vaccines
• Hospitals

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK 
o Spain
o Rest of Europe      
• Asia Pacific
o Japan       
o China       
o India       
o Australia       
o New Zealand      
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter’s five forces analysis, SWOT analysis, etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary          
            
2 Preface           
 2.1 Abstract          
 2.2 Stake Holders         
 2.3 Research Scope         
 2.4 Research Methodology        
  2.4.1 Data Mining        
  2.4.2 Data Analysis        
  2.4.3 Data Validation        
  2.4.4 Research Approach        
 2.5 Research Sources         
  2.5.1 Primary Research Sources       
  2.5.2 Secondary Research Sources       
  2.5.3 Assumptions        
            
3 Market Trend Analysis         
 3.1 Introduction         
 3.2 Drivers          
 3.3 Restraints         
 3.4 Opportunities         
 3.5 Threats          
 3.6 Application Analysis        
 3.7 End User Analysis         
 3.8 Emerging Markets         
 3.9 Impact of Covid-19         
             
4 Porters Five Force Analysis         
 4.1 Bargaining power of suppliers        
 4.2 Bargaining power of buyers        
 4.3 Threat of substitutes        
 4.4 Threat of new entrants        
 4.5 Competitive rivalry         
            
5 Global Viral Vector & Plasmid DNA Manufacturing Market, By Vector Type    
 5.1 Introduction         
 5.2 Viral Vectors         
  5.2.1 Lentiviral Vectors        
  5.2.2 Adenoviral Vectors        
  5.2.3 Retroviral Vectors        
  5.2.4 Adeno-Associated Virus (AAV)      
  5.2.5 Other Viral Vectors        
   5.2.5.1 Simian Virus       
   5.2.5.2 Alphavirus       
   5.2.5.3 Herpes Simplex Virus      
   5.2.5.4 Sendai Virus       
   5.2.5.5 Foamy Virus       
   5.2.5.6 Vaccinia Virus        
 5.3 Non-Viral Vectors         
  5.3.1 Plasmid DNA        
  5.3.2 Liposomes, Lipoplexes and Polyplexes      
  5.3.3 Oligonucleotides        
            
6 Global Viral Vector & Plasmid DNA Manufacturing Market, By Workflow     
 6.1 Introduction         
 6.2 Downstream Processing          
  6.2.1 Fill-Finish          
  6.2.2 Purification          
 6.3 Upstream Processing          
  6.3.1 Vector Recovery/Harvesting        
  6.3.2 Vector Amplification & Expansion      
             
7 Global Viral Vector & Plasmid DNA Manufacturing Market, By Disease     
 7.1 Introduction         
 7.2 Infectious Diseases         
 7.3 Cancer           
 7.4 Genetic Disorders         
            
8 Global Viral Vector & Plasmid DNA Manufacturing Market, By Sales Channel    
 8.1 Introduction         
 8.2 Direct Sales         
 8.3 Channel Sales         
            
9 Global Viral Vector & Plasmid DNA Manufacturing Market, By Application    
 9.1 Introduction         
 9.2 Vaccinology          
 9.3 Antisense & RNAi, & Molecular Therapy       
 9.4 Cell Therapy         
 9.5 Cancer          
 9.6 Viral Infections         
 9.7 Gene Therapy         
 9.8 Inherited Disorders         
 9.9 Viral Vaccines         
 9.10 Protein Expression Studies        
 9.11 Formulation Development        
            
10 Global Viral Vector & Plasmid DNA Manufacturing Market, By End User     
 10.1 Introduction         
 10.2 Pharmaceutical and Biopharmaceutical Companies         
 10.3 Research Institutes         
 10.4 Immunotherapy         
 10.5 DNA Vaccines         
 10.6 Hospitals          
            
11 Global Viral Vector & Plasmid DNA Manufacturing Market, By Geography    
 11.1 Introduction         
 11.2 North America          
  11.2.1 US         
  11.2.2 Canada         
  11.2.3 Mexico         
 11.3 Europe          
  11.3.1 Germany         
  11.3.2 UK         
  11.3.3 Italy         
  11.3.4 France         
  11.3.5 Spain         
  11.3.6 Rest of Europe         
 11.4 Asia Pacific         
  11.4.1 Japan         
  11.4.2 China         
  11.4.3 India         
  11.4.4 Australia         
  11.4.5 New Zealand        
  11.4.6 South Korea        
  11.4.7 Rest of Asia Pacific        
 11.5 South America         
  11.5.1 Argentina        
  11.5.2 Brazil         
  11.5.3 Chile         
  11.5.4 Rest of South America       
 11.6 Middle East & Africa        
  11.6.1 Saudi Arabia        
  11.6.2 UAE         
  11.6.3 Qatar         
  11.6.4 South Africa        
  11.6.5 Rest of Middle East & Africa       
            
12 Key Developments          
 12.1 Agreements, Partnerships, Collaborations and Joint Ventures     
 12.2 Acquisitions & Mergers        
 12.3 New Product Launch         
 12.4 Expansions         
 12.5 Other Key Strategies        
            
13 Company Profiling          
 13.1 Lonza          
 13.2 Catapult           
 13.3 uniQure N.V.         
 13.4 FUJIFILM Diosynth Biotechnologies       
 13.5 Kaneka Eurogentec S.A.        
 13.6 Oxford Biomedica         
 13.7 Spark Therapeutics, Inc.        
 13.8 Cobrabiologics         
 13.9 Merck KGaA         
 13.10 Brammer Bio         
 13.11 Cell and Gene Therapy Catapult       
 13.12 FinVector Vision Therapies        
 13.13 MassBiologics         
 13.14 SIRION Biotech         
 13.15 Thermo Fisher Scientific       

 

Viral Vector & Plasmid DNA Manufacturing - Global Market Outlook (2018-2027)

List of Tables           
1 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Region (2017-2027) ($MN)  
2 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Vector Type (2017-2027) ($MN)  
3 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Viral Vectors (2017-2027) ($MN)  
4 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Lentiviral Vectors (2017-2027) ($MN) 
5 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Adenoviral Vectors (2017-2027) ($MN) 
6 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Retroviral Vectors (2017-2027) ($MN) 
7 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Adeno-Associated Virus (AAV) (2017-2027) ($MN)
8 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Other Viral Vectors (2017-2027) ($MN) 
9 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Non-Viral Vectors (2017-2027) ($MN) 
10 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Plasmid DNA (2017-2027) ($MN)  
11 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Liposomes, Lipoplexes and Polyplexes (2017-2027) ($MN)
12 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Oligonucleotides (2017-2027) ($MN) 
13 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Workflow (2017-2027) ($MN)  
14 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Downstream Processing (2017-2027) ($MN) 
15 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Fill-Finish (2017-2027) ($MN)  
16 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Purification (2017-2027) ($MN)  
17 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Upstream Processing (2017-2027) ($MN) 
18 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Vector Recovery/Harvesting (2017-2027) ($MN)
19 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Vector Amplification & Expansion (2017-2027) ($MN)
20 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Disease (2017-2027) ($MN)  
21 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Infectious Diseases (2017-2027) ($MN) 
22 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Cancer (2017-2027) ($MN)  
23 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Genetic Disorders (2017-2027) ($MN) 
24 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Sales Channel (2017-2027) ($MN)  
25 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Direct Sales (2017-2027) ($MN)  
26 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Channel Sales (2017-2027) ($MN)  
27 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Application (2017-2027) ($MN)  
28 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Vaccinology (2017-2027) ($MN)  
29 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Antisense & RNAi, & Molecular Therapy (2017-2027) ($MN)
30 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Cell Therapy (2017-2027) ($MN)  
31 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Cancer (2017-2027) ($MN)  
32 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Viral Infections (2017-2027) ($MN) 
33 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Gene Therapy (2017-2027) ($MN)  
34 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Inherited Disorders (2017-2027) ($MN) 
35 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Viral Vaccines (2017-2027) ($MN)  
36 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Protein Expression Studies (2017-2027) ($MN)
37 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Formulation Development (2017-2027) ($MN)
38 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By End User (2017-2027) ($MN)  
39 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Pharmaceutical and Biopharmaceutical Companies (2017-2027) ($MN)
40 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Research Institutes (2017-2027) ($MN) 
41 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Immunotherapy (2017-2027) ($MN) 
42 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By DNA Vaccines (2017-2027) ($MN)  
43 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Hospitals (2017-2027) ($MN)  

 

.